Glenn Stoller, MD
Ophthalmology · Rockville Centre, NYNPI 1558366526
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,120 of the $12,659 with a category attached, or 64.1%. 21 manufacturers reported payments, led by Novartis at 53.0% of the total. Reporting peaked in 2019 at $6,723 and has fallen 92.6% since, to $497 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $94.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Genentech USA, Inc.$3K
- AbbVie$760
- Apellis Pharmaceuticals, Inc.$532
- Biotissue Holdings Inc.$420
- Mallinckrodt Hospital Products Inc.$254
- plus $965 from 15 others
Across 205 payments — averaging $10,026 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.5M
- Roche TCRC, Inc.$286K
- Apellis Pharmaceuticals, Inc.$194K
- Regeneron$27K
- Bayer$10K
What the payments were for
- Consulting fees$8,12064%
- Travel & lodging$4043%
- Food & beverage$4,13633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $6,716 |
| Genentech USA, Inc. | 23 | $3,013 |
| AbbVie(2 entities) | 27 | $760 |
| Apellis Pharmaceuticals, Inc. | 5 | $532 |
| Biotissue Holdings Inc. | 11 | $420 |
| Mallinckrodt Hospital Products Inc. | 8 | $254 |
| Harrow Eye, LLC | 3 | $168 |
| Aerie Pharmaceuticals, Inc. | 4 | $165 |
| Regeneron Healthcare Solutions, Inc. | 1 | $139 |
| AstraZeneca | 1 | $100 |
| Coherus Oncology, Inc. | 2 | $59 |
| Bausch & Lomb Americas Inc. | 3 | $57 |
| Amgen | 3 | $53 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Alcon | 2 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,659 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 394 | $7,443 |
| LumiganBimatoprost | 11 | $6,312 |
| Prednisolone Acetate | 127 | $5,014 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $3,939 |
| Difluprednate | 30 | $2,804 |
| Timolol Maleate | 28 | $1,012 |
| Dorzolamide Hcl | 38 | $616 |
| Latanoprost | 38 | $477 |
| MoxifloxacinMoxifloxacin Hcl | 22 | $439 |
| Atropine Sulfate | 11 | $429 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $760 | $10,25125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Rockville Centre
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.